Compare Lowe`s Companies Inc (LOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Lowe`s Companies Inc is far larger — about 10.5× State Street SPDR S&P Biotech ETF's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LOW | XBI | |
|---|---|---|
Market Cap | $105.96B | $10.11B |
Volume | 4,039,547 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $287.39 | $169.55 |
52-Week Low | $179.50 | $104.99 |
Typical Hold Time | 98 Days | 38 Days |
Enterprise Value | $144.81B | — |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with recent earnings beats but faces a bearish technical outlook. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector contends with a slowing housing market.
Wall Street maintains a bullish consensus with a $244.09 price target (60.8% buy ratings), but risks include high debt levels and economic sensitivity. The stock offers value with dividend payments, yet investors must weigh competitive pressures and macroeconomic headwinds against its innovation efforts and market position.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
